pocketful logo
Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

NSE: ZYDUSLIFE BSE: 532321

₹891.90

(-2.08%)

Wed, 06 May 2026, 02:31 am

mtf coin illustrationMTF 5x

Zydus Lifesciences Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    91753.45

  • Net Profit

    4614.80

  • P/B

    3.72

  • Sector P/E

    33.68

  • P/E

    19.69

  • EV/EBITDA

    12.57

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    21.08

  • ROCE

    24.56

  • Debt/Equity

    0.09

  • EPS (TTM)

    50.82

  • Dividend Yield

    1.21

  • Book Value

    251.45

  • Interest Cover

    37.33

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (3.5x coverage).
  • Dividends after 3 years are expected to be well covered by earnings (4.8x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Cadila Healthcare's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
thumbs up icon

Cons

  • Cadila Healthcare's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Cadila Healthcare is expected to decrease over the next 2 years.
  • Cadila Healthcare's net income is expected to increase but not above the 50% threshold in 2 years time.
  • Cadila Healthcare is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
  • Cadila Healthcare's revenue is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters75.0075.0074.9974.9974.99
FII6.957.067.347.137.32
DII11.2011.0910.8611.1311.01
Public6.856.856.806.746.68
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

50.09

MACD

2.62

50 DMA

906.72

200 DMA

943.25

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1151.571024.17958.03896.77830.63769.37641.97
Fibonacci1024.17975.50945.43896.77848.10818.03769.37
Camarilla926.93915.26903.58896.77880.22868.54856.87

Pivots Level: Classic

R3

+254.80

1151.57

R2

+127.40

1024.17

R1

+61.27

958.03

896.77
896.77
Pivot Point
LTP: 912.25

S1

-66.13

830.63

S2

-127.40

769.37

S3

-254.80

641.97

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    914.37

  • 20-EMA

    913.67

  • 30-EMA

    911.37

  • 50-EMA

    909.50

  • 100-EMA

    914.89

  • 200-EMA

    928.02

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
09 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results
25 Jun 2025dividendFinal Dividend - Rs. - 1125 Jul 2025
20 May 2025agm
19 May 2025dividend₹11.00 Dividend /Share25 Jul 2025
26 Jun 2024dividendFinal Dividend - Rs. - 326 Jul 2024
17 May 2024agm
17 May 2024dividend₹3.00 Dividend /Share26 Jul 2024
09 Feb 2024buyback
23 Jan 2024buybackBuy Back of Shares23 Feb 2024

Read More

Peer Comparison

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Read More

Zydus Lifesciences Ltd About

Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.(Source : 202503-Annual Report Page No:291)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

Pankaj R Patel

Employees

Contact

Website icon

Website

http://www.zyduscadila.com

Email icon

Email

dhavalsoni@zyduscadila.com; upen.shah@zyduscadila.

Phone icon

Phone

91-079-26868100

Location icon

Location

Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W, Ahmedabad, Gujarat, 382481

Read More

Zydus Lifesciences Ltd Company History

YearHistory
2020
  • Zydus and CMS entered pact for Desidustat in Greater China.
  • Zydus Wellness launched hand sanitizer under Nycil brand.
  • Zydus Cadila launched COVID-19 drug Remdesivir in India.
  • Zydus Cadila launched new product for COPD patients in India.
2021
  • Zydus Cadila launched Trastuzumab Emtansine under brand Ujvira.
  • Cadila Healthcare received orphan drug designation for malaria treatment compound.
2022
  • Zydus Life received USFDA final approvals for Silodosin and Pregabalin.
  • Zydus Group had 338 approvals and filed over 431 ANDAs.
  • Zydus Life received final USFDA approval for Topiramate extended-release capsules.
  • Zydus Lifesciences' arm received EC approval for MoCD injection.
  • Received Pharma Company of the Year Award, Excellence in CSR, and 7th India Pharma CSR award.
2023
  • Zydus Lifesciences inked licensing pact with Daewoong Pharmaceutical.
  • Zydus Lifesciences received USFDA approval for Acyclovir Cream.
  • Sentynl Therapeutics completed asset transfer of CUTX-101 from Cyprium Therapeutics.
  • Zydus Lifesciences received 7th CSR Health Impact Award.
2024
  • Zydus Lifesciences received WHO prequalification for Typhoid Vi conjugate vaccine.
  • Zydus Lifesciences received Mexican regulatory approval for cancer treatment biosimilar.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
UBS PRINCIPAL CAPITAL ASIA LIMITEDSell67016641128.1130 Aug 2024
INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD.Buy5460159258.2128 May 2019
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFBuy710279740330 Nov 2015
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTFSell555000402.7930 Nov 2015

Read More

Zydus Lifesciences Ltd News

Zydus VTEC Receives ₹9.00 Million CGST Penalty Order

Zydus VTEC Ltd (ZVTEC), a wholly owned subsidiary of Zydus Lifesciences, received a CGST demand and penalty order of Rs. 9.00 million each for alleged inadmissible Input Tax Credit.

05 May 2026

companies

Zydus Lifesciences Completes €360,000 Acquisition

Zydus subsidiary Amplitude SAS acquired 100% stake in French orthopedic distributor Aptitude Orthopedie for €360,000 to internalize commercial capabilities and reduce distribution costs.

02 May 2026

companies

Zydus Subsidiary Acquires FBC Medical for Euro 700,000

Zydus Lifesciences subsidiary Amplitude SAS completed acquisition of 100% stake in French medical equipment distributor FBC Medical for Euro 700,000 to internalize commercial capabilities and reduce distribution costs.

02 May 2026

companies

Zydus Lifesciences Subsidiary Acquires French Firm

Zydus Lifesciences' subsidiary Amplitude SAS has completed the acquisition of full stake in French orthopedic company Aptitude Orthopedie for €360,000, expanding its European operations.

01 May 2026

companies

Zydus Subsidiary Acquires FBC Medical for Euro 700,000

Zydus Lifesciences subsidiary Amplitude SAS acquires 100% stake in FBC Medical, France for Euro 700,000 to internalize commercial capabilities and reduce distribution costs.

01 May 2026

companies

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800